arrow_back Back to App

Drug Price Transparency: Supply Chain Cost Study

This act aims to investigate how prescription drug prices are set and how intermediary compensation affects these prices. This will help citizens better understand why medications cost what they do, potentially leading to future cost-reducing changes. The report is intended to identify potential conflicts of interest and inefficiencies in the system.
Key points
Mandates a comprehensive study of compensation and payment structures throughout the prescription drug supply chain.
Analyzes the impact of intermediaries (e.g., pharmacy benefit managers, wholesalers, pharmacies) on final drug prices.
Identifies potential conflicts of interest that could lead to higher drug prices.
Requires a report to Congress with study findings and recommendations for legislative and administrative actions.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_7535
Sponsor: Rep. Caraveo, Yadira [D-CO-8]
Process start date: 2024-03-05
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Prescription Drug Supply Chain Pricing Transparency Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_7535.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2024-03-05.

What are the main provisions?

Key points include:

  • Mandates a comprehensive study of compensation and payment structures throughout the prescription drug supply chain.
  • Analyzes the impact of intermediaries (e.g., pharmacy benefit managers, wholesalers, pharmacies) on final drug prices.
  • Identifies potential conflicts of interest that could lead to higher drug prices.
  • Requires a report to Congress with study findings and recommendations for legislative and administrative actions.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Caraveo, Yadira [D-CO-8].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health Economy